Tralokinumab Dosage

Medically reviewed by Drugs.com. Last updated on Mar 21, 2024.

Usual Adult Dose for Atopic Dermatitis

Initial dose: 600 mg subcutaneously once
Maintenance dose (after initial dose): 300 mg subcutaneously every other week

• After 16 weeks of therapy: 300 mg subcutaneously every 4 weeks may be considered for patients below 100 kg who achieved clear or almost clear skin

Comments:

• Treatment should be initiated by health care providers experienced in the diagnosis and treatment of atopic dermatitis.
• Before starting this drug, all age-appropriate vaccinations (as recommended by current immunization guidelines) should be completed.
• This drug can be used with or without topical corticosteroids.
• Topical calcineurin inhibitors may be used, but should be reserved for problem areas (face, neck, intertriginous, and genital).

Use: For the treatment of moderate to severe atopic dermatitis when the disease is not adequately controlled with topical prescription agents or when such agents are not advisable

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Known hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Administer by subcutaneous injection.
• Before injection, remove the prefilled syringes from the refrigerator and allow them to reach room temperature without removing the cap.
• The solution should be clear and colorless or pale yellow. Do not use if cloudy, or if it contains visible particulate matter.
• This drug is intended for use under the guidance of a health care professional; however, a patient can be trained to self-inject. Provide proper training to patients or caregivers.
• Administer the initial 600 mg dose as four 150 mg subcutaneous injections at different injection sites within the same body area.
• Subsequent 300 mg doses should be administered as two 150 mg subcutaneous injections at different injection sites within the same body area.
• Subcutaneous injections can be administered into the thigh or abdomen area (except for the 2 inches around the navel), or the upper arm. Rotate body areas with each subsequent set of injections.
• Do not inject into skin that is tender, damaged, bruised, or scarred.
• Discard any product left in the syringe after administration.
• Administer any missed dose as soon as possible and then continue with the regular scheduled time.

Storage requirements:

• Store in refrigerator between 2C and 8C (36F to 46F) in original carton to protect from light. Do not freeze.
• Before injection remove from the refrigerator and allow the prefilled syringes to reach room temperature. May be kept at room temperature for up to 14 days
• Do not shake prefilled syringes, and do not expose to heat or direct sunlight.

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).

Frequently asked questions

• What are the most common skin conditions? (with photos)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer